VVOS News and Press, Vivos Therapeutics Inc. From 01/04/23

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obst...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, is reporting on its second and third quarter of 2022. Acc...

Vivos Therapeutics, Inc. (VVOS) Q2 and Q3 2022 Earnings Conference Call December 20, 2022, 17:00 PM ET Company Participants Julie Gannon - Chief of Staff and Investor Relations Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer ...

Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or ...

HIGHLANDS RANCH, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderat...

LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new ...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has received a compliance notice from the Listing Q...

LITTLETON, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (&#...

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today provided an upd...

Detailed Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements Restated ...